The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial
- 1 March 2017
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 185, 93-100
- https://doi.org/10.1016/j.ahj.2016.12.004
Abstract
No abstract availableFunding Information
- Portola Pharmaceuticals, Inc
- Portola Pharmaceuticals, Inc
This publication has 8 references indexed in Scilit:
- Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsThe New England Journal of Medicine, 2016
- Epidemiology of venous thromboembolismNature Reviews Cardiology, 2015
- Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendmentAmerican Heart Journal, 2014
- The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) studyAmerican Heart Journal, 2013
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)European Heart Journal, 2013
- Executive SummarySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitorBioorganic & Medicinal Chemistry Letters, 2009
- Venous thromboembolism (VTE) in EuropeThrombosis and Haemostasis, 2007